Abstract 6171
Background
Clinical trials using immune checkpoint inhibitors (ICPIs) against immune inhibitory receptor ligand 1 (PD-L1) have failed to show clinical benefit for glioblastoma (GBM) patients. This is likely due to multiple factors, including but not limited to, the immunologically cold GBM microenvironment lacking effector immune cells. PD-L1 expression in tumour cells can be regulated by epidermal growth factor receptor/janus kinase 2 (EGFR/JAK2) signalling that might weaken the antitumor immune response by increasing PD-L1 level. Furthermore, EGFR is mutationally activated in approximately 50% of GBMs. Therefore, we analysed changes in EGFR and PD-L1 expression levels in the intraoperative specimens obtained from patients diagnosed with primary GBMs.
Methods
In total, 27 patients with newly diagnosed GBM underwent surgery and were investigated for mRNA and protein expression level either of Ki67, EGFR/EGFRvIII and PD-L1 by quantitative reverse transcription-PCR (qRT-PCR) or immunohistochemistry (IHC).
Results
EGFR overexpression (IHC H-score > 200 [0-300]) was detected in 8/27(30%) specimens as assessed by IHC, whereas 25/27 samples (93%) showed increased EGFR mRNA expression, suggesting a higher sensitivity of qRT-PCR analysis. Of the 25, 10 patients were harbouring EGFRvIII mutation. PD-L1 protein expression (2+ and 3+ staining in > 5% cells) was present in 16/27(60%) samples, of which concurrent elevation of PD-L1 and EGFR mRNA copy numbers was seen in 9/16 samples. In contrast, IHC revealed EGFR overexpression in only 2/16 PDL-1 positive patients. Ki67 staining revealed great variety in proliferation status of the GBMs, with a median Ki67 index of 30 (range 10-62).
Conclusions
Collectively, these results confirm that primary GBMs are characterised by a considerable heterogeneity of EGFR, EGFRvIII and PD-L1 expressions at both mRNA and protein levels. The PD-L1 mRNA expression was found to be associated with EGFR mRNA copy number only in small group of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NCNOPUS13#2017/25/B/NZ5/00039, KNW-1-108/N/8/O.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract